ArticlePreventive medicine2020
E-cigarettes: How can they help smokers quit without addicting a new generation?
Article in Preventive medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Assessment of Abuse Liability and Nicotine Pharmacokinetics of glo Heated Tobacco Products in a Randomized, Crossover Study.European journal of drug metabolism and pharmacokinetics · 2024Trial
- An assessment of nicotine pharmacokinetics and subjective effects of the pulze heated tobacco system compared with cigarettes.Scientific reports · 2023Trial
- Navigating regulatory challenges: a cross-sectional survey of vaping and smoking behaviours among university students in Yunnan, China.BMC public health · 2026Article
- Assessment of nicotine pharmacokinetics and abuse liability in randomized, crossover studies of Vuse Alto electronic nicotine delivery systems.Frontiers in pharmacology · 2026Article
- Menthol flavour enhances vaping experiences: a randomised crossover clinical trial.Tobacco control · 2025Article
- Review
- Nicotine e-cigarettes for smoking cessation: a clinical pharmacology perspective.Expert review of clinical pharmacology · 2025Review
- Randomized crossover clinical studies to assess abuse liability and nicotine pharmacokinetics of Velo Oral Nicotine pouches.Frontiers in pharmacology · 2025Article
- Association between type of smoking and smoking cessation plans in Korean adults: A nationwide cross-sectional study.Tobacco induced diseases · 2025Article
- Assessment of heated herbal products' tobacco harm reduction potential: pre-clinical and clinical studies.Frontiers in toxicology · 2025Article
- Effect of menthol/mint-flavored pods on young JUUL E-cigarette users' subjective experience, puffing behavior, and nicotine exposure: A pilot study.Drug and alcohol dependence · 2022Article
- "When I Don't Have a Cigarette It's Helpful, but It Really Don't Satisfy:" Qualitative Study of Electronic Nicotine Delivery Systems (ENDS) Use among Low-Income Smokers.International journal of environmental research and public health · 2022Article
- Balancing Consideration of the Risks and Benefits of E-Cigarettes.American journal of public health · 2021Article
- Behavior change, health, and health disparities 2020: Some current challenges in tobacco control and regulatory science.Preventive medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The dramatic increase in youth use of electronic nicotine delivery systems (ENDS; e.g., e-cigarettes) in the United States has focused regulatory efforts to address this concern while still encouraging smokers to switch completely to lower risk products or quit all tobacco product use. Increases in the minimum age for purchase of all tobacco products and changes in enforcement policy for ENDS have been recently enacted in an effort to address the youth vaping epidemic. Since all ENDS marketed after February 15, 2007 will be required to meet the "appropriate for the protection of public health" standard for marketing authorization of new products, ENDS manufacturers will have to demonstrate, in part, that their products help lessen the adverse impact on youth use. Some, such as disallowing flavors other than tobacco or menthol or limiting nicotine delivery, may help reduce youth use but could also inhibit smokers from quitting smoking. Other approaches, including reducing the high-tech appearance and discreteness of ENDS, discontinuing use of coupons and two-for-one type price incentives for ENDS, limiting retail sales of these products to adult-only facilities, and incorporating technological innovations such as biometrics or geofencing into ENDS, may help manufacturers demonstrate that marketing of their products would help reduce youth use of ENDS and lessen the epidemic, while still assuring adult smokers have access to products that encourage discontinuing combusted product use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.